ArticleCell communication and signaling : CCS2025
Singapore grouper iridovirus utilizes Rab1 to facilitate viral trafficking and evade the immune response by targeting the STING-IRF3 pathway.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe phylum Nucleocytoviricota comprises diverse nucleocytoplasmic large DNA viruses (NCLDVs) that infect a wide range of eukaryotic hosts, yet the mechanisms underlying their intracellular transport and immune evasion remain poorly understood. Singapore grouper iridovirus (SGIV), a representative NCLDV, is a major pathogen in marine aquaculture. Rab GTPases are central regulators of vesicular trafficking and frequent targets of viral manipulation, but their roles in SGIV infection have not been elucidated. Here, we investigated the roles of Rab1 from Epinephelus coioides (EcRab1) during SGIV infection.
methodsOrange-spotted grouper (E. coioides) and grouper spleen (GS) cells were used in this study. The immunoblotting and qRT-PCR were used for measuring the expression of proteins and mRNAs. Viral entry and trafficking were analyzed by single-particle imaging and live-cell imaging, respectively. Immunofluorescence staining was employed to detect the location of proteins and organelle. siRNA or shRNA was used to knock down gene expression in cultured cells in vitro. The interaction between proteins was investigated by co-immunoprecipitation assay and confocal imaging.
resultsSGIV infection markedly downregulated EcRab1, and both overexpression and silencing of EcRab1 significantly altered viral replication. EcRab1 promoted viral entry and delivery to early endosomes (EEs) via interaction with Rab5, generating transient Rab1+/Rab5+ vesicles that matured into Rab5+ vesicles. In addition to its role in trafficking, EcRab1 maintained the structural integrity of the Golgi apparatus and mediated the transport of STING from the endoplasmic reticulum to the Golgi, thereby enhancing the production of IFN-I. SGIV counteracted these processes through the action of its protein VP20, which bound both GDP- and GTP-loaded forms of EcRab1, inhibited the association between STING and EcRab1, and prevented the localization of STING to the Golgi. Moreover, the VP20–EcRab1 complex facilitated the recruitment of IRF3 to autophagosomes for degradation, thus attenuating antiviral signaling pathways.
conclusionsOur findings reveal that SGIV hijacks host EcRab1 to promote trafficking to early endosomes while simultaneously disrupting STING–IRF3 signaling, thereby facilitating viral replication and immune evasion. This study reveals a novel mechanism through which Rab1 contributes to large DNA virus infection and suggests that Rab1 could serve as a potential antiviral target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.